Ben Around

FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG

CYTR has the potential to fly, because there is little notice of the secondary use of arimoclomol in treating stroke victims up to 48 hours after the initial stroke.

The stroke treatment possibilities and the 45% stake in RXII are the reason I am very long on this stock.

Do your own DD.

"Arimoclomol is an orally administered molecular chaperone regulator drug candidate that is being considered as a treatment for ALS and stroke recovery. Molecular chaperone regulator drugs are believed to function by regulating a normal cellular protein repair pathway through the activation or inhibition of “molecular chaperones.” Molecular chaperones detect proteins that are misfolded, and have the ability to refold those proteins into the appropriate, non-toxic shape.

In February 2009, CytRx announced the commencement of a Phase 2/3 adaptive clinical trial, sponsored by the ALS Association and the FDA’s Office of Orphan Products Development OOPD, to study arimoclomol in a subset of patients with the inherited or familial form of ALS. In March 2009, the Company reported that arimoclomol had demonstrated statistically significant neurorestorative results in a preclinical embolic stroke trial. This data supported previous preclinical results indicating improvement in stroke recovery following oral arimoclomol administration up to 48 hours post-stroke."

See the article @
finance.yahoo.com/news...